Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Dropped Today

By Prosper Junior Bakiny – Sep 2, 2020 at 4:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company continues to give up the gains it earned earlier this year.

What happened?

Shares of Inovio Pharmaceuticals (INO -3.39%) closed Wednesday's trading session down by 6.8% after dropping by as much as 12.3% earlier in the day, despite the company not reporting any news. However, the biotech stock has been in sell-off mode for the past month (or so), and today is likely a continuation of that trend. 

So what

Inovio's stock went on a tear during the first half of the year -- gaining as much as 860% -- mostly thanks to its efforts to develop a vaccine for COVID-19. But the company's stock plunged after it released interim data from its phase 1 clinical trial for its coronavirus vaccine candidate, INO-4800, on Jun. 30. And although the biotech somewhat recovered from this setback, its shares started dropping again and gave up more than 40% in August. There are several factors fueling these losses for Inovio. 

Five downward pointing arrows on a blackboard.

Image source: Getty Images.

First, the race to develop a vaccine for COVID-19 is intensifying, and several companies have already started phase 3 clinical studies for their candidates. Since Inovio's valuation is, to a large extent, tied to its COVID-19 programs, the fact that some of its peers seem more likely to cross the finish line before it does isn't good news for the company. Second, despite its recent woes, Inovio's stock is still up by an impressive 219.7% year to date (as of this writing). Some investors are likely choosing to cash in on these gains while they still can. 

Now what

Inovio's stock will remain volatile moving forward, but the most important thing for investors is to focus on the progress of its coronavirus program. The company plans on starting a phase 2/3 clinical trial for INO-4800 this month, and pending regulatory approval, Inovio could produce 100 million doses of its candidate in 2021. If that happens, and considering the market for a coronavirus vaccine spans the globe, Inovio should be able to generate some healthy revenue next year. In other words, there is still hope that this biotech can perform well from here on out. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.71 (-3.39%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.